Joo Mee Kim
Ms. Kim has been practicing across the full spectrum of intellectual property law for over 20 years. Ms. Kim’s practice focuses on litigating patent cases and counseling clients for obtaining, licensing, and enforcing patents in various technologies, including the pharmaceutical, biotechnology, chemical, electronics, and mechanical areas.
Ms. Kim has a broad range of experience in patent matters both in the United States and Korea. She has extensive experience in patent litigation, including Hatch-Waxman litigation and patent troll litigation, both in district courts and at the Court of Appeals for the Federal Circuit. Ms. Kim has litigated on behalf of Mylan Pharmaceuticals, Rexall, Inc., Nature’s Bounty, and LG Electronics, among others.
Ms. Kim also has considerable experience handling post-grant proceedings created by the America Invents Act, and she has particular expertise representing both petitioners and patent owners in IPR proceedings.
Ms. Kim counsels clients in the pharmaceutical, biotechnology, chemical, biomedical, and electronic areas on strategic exploitation of patents, including maximizing licensing revenue and developing effective defenses against infringement allegations. She also provides written opinions to evaluate freedom-to-operate, invalidity, and/or infringement issues for clients in the technical fields of pharmaceuticals, genetic engineering, molecular biology, monoclonal antibodies, cancer treatments, and protein production in plants.
Ms. Kim is a past President of the Korean American Intellectual Property Bar Association (“KAIPBA”) and she served on the U.S. preparation committee for the US-Korea Judicial Conference hosted by the Federal Circuit and the Korean Patent Court in 2013. Ms. Kim has been selected as a Washington DC Super Lawyer in the fields of Intellectual Property Litigation and Intellectual Property (2014-2019). She is a frequent guest speaker and lecturer at conferences hosted by the Korean Intellectual Property Office and various Associations.
Areas of Concentration
- Developing Pre-Litigation Strategy
- Opinion of Counsel: Patentability, Freedom-to-Operate, Infringement, Invalidity
- Federal District Court
- Trade Secrets
- Hatch-Waxman Litigation
- Patent Prosecution
- Biology and Biotechnology
- Medical Devices
Publications & Presentations
"Patent Law Perspective on the Report of the Federal Trade Commission on Balancing Competition and Patent Law and Policy" written by E. Anthony Figg, C. Nichole Gifford and Joo Mee Kim, presented to the ABA Section of Antitrust Law, May 2004.
"How the 2003 Hatch-Waxman Reform Has Changed NDA/Generic Practice in the U.S,” presented at the Symposium sponsored by Darae Law & Patent Firm, November 9, 2005.
"The Norvasc CAFC Decision and Thereafter,” presented at the Symposium sponsored by Daily Pharm, June 21, 2007, Korea.
"Obviousness after KSR," presented at the Symposium sponsored by Daily Pharm, June 21, 2007, Seoul, Korea.
“U.S. Generic Market,” -- taught in the program entitled “Strategies for Exporting Pharmaceutical Products to the U.S. Market,” sponsored by Korea Health Industry Development Institute and Pharmaceutical Industries, October 12, 2007.
Professional Affiliations, Honors & Recognition
Third President of the Korean-American Intellectual Property Lawyers Association ("
Washington DC Super Lawyer in the field of Intellectual Property Litigation and in the field of Intellectual Property (2014-2019)